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Ulcerogenic potentialAbstract A series of novel ethyl-5-amino-3-methylthio-1H-pyrazole-4-carboxylates 3a–j were syn-
thesized from condensation of various hydrazides 2a–j with ketene dithioacetal. The synthesized
compounds were screened for in vivo analgesic and anti-inﬂammatory activities using acetic acid
writhing test in mice and carrageenan-induced paw edema test in rat, respectively. Diclofenac
sodium was used as a standard drug for comparison. Compounds 3a, 3c and 3d exhibited signiﬁcant
analgesic and anti-inﬂammatory activities at a dose of 25 mg/kg and showed quite less ulcerogenic
index in the range of 0.9–1.12 whereas diclofenac sodium showed 3.10.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are one of
the most useful clinical therapies for the treatment of pain, fe-
ver and inﬂammation (Singh and Triadaﬁlopoulos, 1999). The
major mechanism by which NSAIDs exert, their anti-inﬂam-
matory activity is by the inhibition of cyclooxygenase-derived
prostaglandin synthesis. The chronic use of NSAIDs leads to
gastrointestinal (Botting, 2006), renal (Schneider et al., 2006)
and hepatic (Adebayo and Bjarnason, 2006) side effects. The
prostaglandin synthase (cyclooxygenase), the key enzyme ofinﬂammatory process and an important target of most of the
currently used NSAIDs, exists in two isoforms (COX-1 and
COX-2), COX-1 plays a cytoprotective role while COX-2 in-
duced at the time of injury, causes inﬂammation, pain and fe-
ver (Weilin et al., 1992). The conventional NSAIDs cause
inhibition of both enzymes, thus exhibit anti-inﬂammatory
activity along with gastrointestinal (GI) toxicity on extended
use. The association of COX-2 with induced inﬂammation
has led to the hypothesis that selective inhibition of COX-2
over COX-1 might provide good anti-inﬂammatory activity
with reduced side effects than classical NSAIDs. Therefore,
selective COX-2 inhibitors (coxibs) with better safety proﬁle
have been marketed as a new generation NSAIDs but careful
prospective examination of coxibs has revealed unexpected
cardiovascular adverse effect (Dogne and Pratico, 2005).
The widely prescribed anti-inﬂammatory pyrazole deriva-
tives such as Celecoxib, Deracoxib, Remifenazone and Kebuz-
one (Fig. 1) are COX inhibitors with reduced ulcerogenic side
effects. The literature survey reveals that pyrazoles showed
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Figure. 1 Structure of marketed NSAIDs and synthesized
compound 3a.
260 S.N. Thore et al.excellent antiinﬂammatory, analgesic (Prokopp et al., 2006;
Gyorgy et al., 2008; Morshed et al., 2009; Sung et al., 2011),
antimicrobial (Pimerova and Voronina, 2001; Bekhit et al.,
2008), antiviral, and anti-tumor (Park et al., 2005) activities.
Motivated by the aforesaid ﬁndings and pursuing our stud-
ies on pyrazole moiety, we have synthesized a new series of
ethyl-1H-pyrazole-4-carboxylates 3a–j (Schemes 1 and 2).
Their antiinﬂammatory and analgesic activities were recorded.
Synthesized compounds were characterized on the basis of
their spectral data.
2. Experimental
2.1. Materials
The chemicals were purchased from Aldrich and Merck.
Reagents and solvents were of analytical grade.CH3S
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Scheme 1 Synthesis of Pyr2.2. Instrumentation
The progress of reactions was monitored on aluminum silica
gel 60 F254 (Merck) using chloroform–methanol (9:1 by vol-
ume) as an eluent. Iodine vapors and U.V. light (wavelength
254 nm) were used as visualizing agents. Melting points were
recorded on a Buchi capillary melting point apparatus and
are uncorrected. IR spectra were recorded on a Perkin-Elmer
157 spectrometer using KBr pellets. The 1H NMR spectra on
a Bucker WM-400 (400 MHZ FT NMR) spectrophotometer
were recorded using CDCl3 and DMSO-d6 as solvents with
TMS as an internal reference. Chemical shifts (d) are expressed
in ppm and coupling constants (J) were measured in Hz. Mass
spectra were obtained on a JEOL-SX-102 instrument using
electron impact ionization. Elemental analyses were performed
on Perkin Elmer Auto system 240c analyzer and were within
±0.4% of the theoretical values.
2.3. General method for the synthesis of ethyl-5-amino-3-
methylthio-1H-pyrazole-4-carboxylate 3a–j
A mixture of 1 (Jensen and Henrikesen, 1968) (10 mmol) and
hydrazides 2 (10 mmol) in DMF (5 ml) in the presence of cat-
alytic amount of anhydrous K2CO3 was reﬂuxed for 2–3 h.
The reaction mixture was cooled and poured in ice cold water.
The solid obtained was ﬁltered, washed with water and recrys-
tallized from ethanol to give 3. The physical data of products
are given in Table 1.
2.3.1. Ethyl-5-amino-3-methylthio-1-(4-sulfonamidophenyl)-
1H-pyrazole-4-carboxylate (3a)
IR (KBr, cm1) 3454, 3329 (NH2), 1730 (C‚O), 1325, 1153
(S‚O O). 1H NMR (400 MHz, DMSO d6) d ppm: 1.26
(t, 3H, J= 6.94 Hz, CH2CH3), 2.48 (s, 3H, SCH3), 3.85 (q,
2H, J= 7.0 Hz, CH2CH3), 5.45 (bs, 2H, NH2), 6.59 (bs, 2H,
SO2NH2), 7.80 (d, 2H, J= 8.40 Hz, Ar–H), 7.94 (d, 2H,
J= 8.40 Hz, Ar–H). MS (EI) m/z: 357 [M+1], Anal. Cald.
for C13H16N4O4S2 (356.42): C, 43.81; H, 4.52; N, 15.72.
Found: C, 43.80; H, 4.50; N, 15.69.SCH3
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Scheme 2 Synthesis of Pyrazole derivatives (3i and 3j).
Table 1 Physical data of synthesized compounds (3a–j).
Compound R M.P. (C) Yield (%)
3a
SO2NH2
120–123 71
3b
N
N N
175–178 78
3c
S
O
O
190–195 78
3d
S
O
O
202–205 81
3e
O
O 98–101 82
3f
O
S 130–133 87
3g
N
O
162–165 73
3h
N
O 180–183 75
3i
N
O
H
H
152–155 45
3j
N
O
H
142–145 52
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methyl] phenyl)-1H-pyrazole-4-carboxylate (3b)
IR (KBr, cm1) 3440, 3310 (NH2), 1740 (C‚O).
1H NMR
(400 MHz, DMSO d6) d ppm: 1.30 (t, 3H, J= 7.11 Hz,
CH2CH3), 2.57 (s, 3H, SCH3), 3.94 (q, 2H, J= 7.15 Hz,
CH2CH3), 4.99 (s, 2H, CH2), 5.60 (bs, 2H, NH2), 7.15 (d,
2H, J= 8.00 Hz, Ar–H), 7. 24 (d, 2H, J= 8.00 Hz, Ar–H),
8.15 (s, 1H, 1,2,4-triazole–H), 8.23 (s, 1H, 1,2,4-triazole–H).
MS (EI) m/z: 359 [M+1], Anal. Cald. for C16H18N6O2S
(358.42): C, 53.62; H, 5.06; N, 23.45. Found: C, 53.56; H,
5.00; N, 23.44.
2.3.3. Ethyl-5-amino-3-methylthio-1-phenylsulfonyl-1H-
pyrazole-4-carboxylate (3c)
IR (KBr, cm1) 3420, 3190 (NH2), 1750 (C‚O), 1320, 1150
(S‚O). 1H NMR (400 MHz, CDCl3) d ppm: 1.32 (t, 3H,
J= 6.92 Hz, CH2CH3), 2.42 (s, 3H, SCH3), 4.26 (q, 2H,
J= 6.98 Hz, CH2CH3), 5.69 (bs, 2H, NH2), 7.30–7.94 (m,
5H, Ar-H). MS (EI) m/z: 342 [M+1], Anal. Cald. for
C13H15N3O4S2 (341.41): C, 45.74; H, 4.43; N, 12.31. Found:
C, 45.73; H, 4.40; N, 12.28.2.3.4. Ethyl-5-amino-3-methylthio-1-(4-methylphenylsulfonyl)-
1H-pyrazole-4-carboxylate (3d)
IR (KBr, cm1): 3390, 3250 (NH2), 1750 (C‚O), 1310, 1140
(S‚O) . 1H NMR (400 MHz, CDCl3) d ppm: 1.30 (t, 3H,
J= 6.94 Hz, CH2CH3), 2.40 (s, 3H, CH3), 2.48 (s, 3H,
SCH3), 4.28 (q, 2H, J= 7.05 Hz, CH2CH3), 5.60 (bs, 2H,
NH2), 7.34 (d, 2H, J= 8.26 Hz, Ar–H), 7.89 (d, 2H,
J= 8.26 Hz, Ar–H). MS (EI) m/z: 356 [M+1], Anal. Cald.
for C14H17N3O4S2 (355.44): C, 47.31; H, 4.82; N, 11.82.
Found: C, 47.31; H, 4.80; N, 11.78.2.3.5. Ethyl-5-amino-1-(2-furanoyl)-3-methylthio-1H-pyrazole-
4-carboxylate (3e)
IR: (KBr, cm1): 3320, 3250 (NH2), 1750 (C‚O of
ester), 1710 (C‚O of ketone). 1H NMR (400 MHz, CDCl3)
d ppm: 1.44 (t, 3H, J= 6.91 Hz, CH2CH3), 2.55 (s, 3H,
SCH3), 4.38 (q, 2H, J= 7.02 Hz, CH2CH3), 5.52 (bs, 2H,
NH2),6.60 (t, 1H, J= 5.33, Furan-H), 7.34 (d, 1H,
J= 3.42 Hz, Furan-H), 7 .60 (d, 1H, J= 1.76 Hz, Furan-
H). MS (EI) m/z: 296 [M+1], Anal. Cald for C12H13N3O4S
(295.32): C, 48.81; H, 4.44; N, 14.23. Found: C, 48.78; H,
4.42; N, 14.21.
Table 2 Analgesic activity of title compounds (3a–j) against
acetic acid induced writhing tests in mice.
Compounds No. of writhes in
15 min after treatment
(mean ± SEM)
% Inhibition
Control 30.4 ± 1.80** –
Diclofenac sod. 11.2 ± 1.12** 63.15
3a 13.2 ± 0.66** 56.57
3b 16.6 ± 1.20** 45.39
3c 14.4 ± 0.86** 52.63
3d 13.8 ± 1.08** 54.60
3e 17.8 ± 0.72** 41.44
3f 17.2 ± 1.12** 43.42
3g 18.4 ± 1.11** 39.47
3h 18.8 ± 0.67** 38.15
3i 22.4 ± 0.78** 26.31
3j 23.2 ± 0.33** 23.68
Data analyzed by one-way ANOVA followed by Dunnett’s test,
(n= 6).
Dose levels: Test compounds and diclofenac sodium (25 mg/kg b.w.
p.o).
** P< 0.01 signiﬁcant from control.
262 S.N. Thore et al.2.3.6. Ethyl-5-amino-3-methylthio-1-(2-thiophenoyl)-1H-
pyrazole-4-carboxylate (3f)
IR (KBr, cm1): 3380, 3190 (NH2), 1740 (C‚O of ester),
1715 (C‚O of ketone). 1H NMR (400 MHz, CDCl3) d
ppm: 1.40 (t, 3H, J= 6.94 Hz, CH2CH3), 2.48 (s, 3H,
SCH3), 4.29 (q, 2H, J= 7.01 Hz, CH2CH3), 5.62 (bs, 2H,
NH2),7.05 (t, 1H, J= 6.21, Thiophene-H), 7.61 (d, 1H,
J= 4.94 Hz, Thiophene-H), 7.66 (d, 1H, J= 3.87 Hz, Thio-
phene-H). MS (EI) m/z: 312 [M+1], Anal. Cald. for
C12H13N3O3S2 (311.38): C, 46.29; H, 4.21; N, 13.49. Found:
C, 46.28; H, 4.20; N, 13.40.
2.3.7. Ethyl-5-amino-3-methylthio-1-(2-pyridinoyl)-1H-
pyrazole-4-carboxylate (3g)
IR (KBr, cm1): 3370, 3175 (NH2), 1720 (C‚O of ester), 1705
(C‚O of ketone). 1H NMR (400 MHz, DMSO d6) d ppm:
1.23 (t, 3H, 6.92 Hz,CH2CH3), 2.48 (s, 3H, SCH3), 4.20 (q,
2H, 6.98 Hz,CH2CH3), 5.58 (bs, 2H, NH2), 7.60 (t, 1H,
J= 7.94, Pyridine-H), 8.26 (t, 1H, J= 7.33, Pyridine-H), 8
.76 (d, 1H, J= 4.95 Hz, Pyridine-H), 9 .09 (d, 1H,
J= 3.90 Hz, Pyridine -H). MS (EI) m/z: 307 [M+1], Anal.
Cald. for C13H14N4O3S (306.35): C, 50.97; H, 4.61; N, 18.29.
Found: C, 50.80; H, 4.60; N, 18.21.
2.3.8. Ethyl-5-amino-3-methylthio-1-(3-pyridinoyl)-1H-
pyrazole-4-carboxylate (3h)
IR (KBr, cm1): 3375, 3170 (NH2), 1740 (C‚O of ester), 1705
(C‚O of ketone). 1H NMR (400 MHz, DMSO d6) d ppm:
1.30 (t, 3H, 6.94 Hz,CH2CH3), 2.51 (s, 3H, SCH3), 4.22 (q,
2H, 6.98 Hz, CH2CH3), 5.65 (bs, 2H, NH2), 7.64 (t, 1H,
J= 7.70 Hz, Pyridine-H), 8.30 (d, 1H, J= 4.70 Hz, Pyri-
dine-H), 8.79 (d, 1H, 4.64 Hz, Pyridine-H), 9.12 (s, 1H, Pyri-
dine-H). MS (EI) m/z: 307 [M+1], Anal. Cald. for
C13H14N4O3S (306.35): C, 50.97; H, 4.61; N, 18.29. Found:
C, 50.85; H, 4.61; N, 18.23.
2.3.9. Ethyl-5-amino-1-glycinoyl-3-methylthio-1H-pyrazole-4-
carboxylate (3i)
IR (KBr, cm1): 3390, 3195 (NH2), 1734 (C‚O of ester), 1701
(C‚O of ketone). 1H NMR (400 MHz, CDCl3) d ppm: 1.30 (t,
3H, 6.92 Hz, CH2CH3), 2.45 (bs, 2H, glycinyl NH2), 2.55 (s,
3H, SCH3), 3.80 (s, 2H, CH2 of glycinyl), 4.29 (q, 2H,
7.0 Hz, CH2CH3), 5.70 (bs, 2H, NH2). MS (EI) m/z: 259
[M+1], Anal. Cald. for C9H14N4O3S (258.30): C, 41.85; H,
5.46; N, 21.69. Found: C, 41.84; H, 5.42; N, 21.65.
2.3.10. Ethyl-5-amino-3-methylthio-1-(4-piperidinoyl)-1H-
pyrazole-4-carboxylate (3j)
IR (KBr, cm1): 3380, 3295 (NH2), 3250 (NH), 1742 (C‚O of
ester), 1703 (C‚O of ketone). 1H NMR (400 MHz, CDCl3) d
ppm: 1.30 (t, 3H, 6.94 Hz, CH2CH3), 1.91 (m, 4H, CH2 of
piperidinyl), 2.30 (bs, 1H, NH), 2.38 (m, 2H, CH2 of piperid-
inyl), 2.47 (s, 3H, SCH3), 2.80 (m, 4H, CH2 of piperidinyl)
4.31 (q, 2H, 7.06 Hz, CH2CH3), 5.70 (bs, 2H, NH2). MS (EI)
m/z: 313 [M+1], Anal. Cald. for C13H20N4O3S (312.39): C,
49.98; H, 6.45; N, 17.93. Found: C, 49.90; H, 6.42; N, 17.87.
2.4. Pharmacological evaluation
Synthesized compounds 3a–j were investigated for anti-inﬂam-
matory and analgesic activities and most active representatives3a, 3c, and 3d of the series were investigated for acute ulcerog-
enicity. Diclofenac sodium was used as a reference standard at
a dose of 25 mg/kg for anti-inﬂammatory, analgesic and
ulcerogenicity studies. The experiments were performed on
Albino rats of Wistar strain of either sex, weighing 150–
180 g for anti-inﬂammatory activity and Swiss Albino mice
of either sex weighing 25–30 g for analgesic activity. The ani-
mals were divided into groups (control, reference and test
groups) of 6 animals each.The tested compounds and the stan-
dard drugs were administered in the form of a suspension
(using 1% carboxymethylcellulose) in distill water by oral
route of administration for analgesic, anti-inﬂammatory and
ulcerogenicity studies. The animals were maintained in colony
cages at 25 ± 2 C, relative humidity 45–55%, under a 12 h
light–dark cycle; they were fed standard animal feed. All the
animals were acclimatized for a week before use.
2.4.1. Analgesic activity
Analgesic activity was evaluated using acetic acid induced
writhing method (Koster et al., 1959). After 50 min of the oral
administration of test compound and standard drug, each ani-
mal was injected with 0.25 ml of 0.6% v/v acetic acid solution
intraperitoneally. After 10 min of acetic acid injection, the
numbers of muscular contractions (writhings) in mice were
counted for a period of 15 min. A signiﬁcant reduction in the
number of writhing by any treatment as compared to control
animals was considered as a positive analgesic response. The
average number of writhes in each group of treated mice was
compared with that of the control. The inhibition % was cal-
culated and reported in Table 2.
2.4.2. Anti-inﬂammatory activity
Anti-inﬂammatory activity was evaluated using carrageenan
induced rat paw edema method (Winter et al., 1962). Carra-
geenan solution (0.1% in sterile 0.9% NaCl solution) in a vol-
ume of 0.1 mL was injected subcutaneously into the subplantar
region of the right hind paw of each rat. One group was kept as
control and the animals of the other group were pretreated with
Table 3 Results of anti-inﬂammatory activity of title compounds (3a–j) against carrageenan induced rat paw edema model in rats.
Compd. Change in paw volume in (ml) after drug treatment (±SEM) Anti-inﬂammatory activity (% inhibition)
0 h 1 h 2 h 3 h 1 h 2 h 3 h
Control 0.580 ± 0.29* 0.920 ± 0.27* 1.160 ± 0.30* 1.250 ± 0.32* – – –
Diclofenac 0.576 ± 1.60* 0.792 ± 1.67* 0.888 ± 1.37* 0.974 ± 1.39* 36.47 46.20 40.56
3a 0.612 ± 1.36* 0.842 ± 1.52* 0.934 ± 1.32* 1.022 ± 1.41* 32.35 44.48 38.80
3b 0.575 ± 1.07* 0.842 ± 1.28* 0.963 ± 1.39* 1.035 ± 1.38* 21.47 33.10 31.34
3c 0.592 ± 1.57** 0.829 ± 1.90** 0.917 ± 1.33** 1.012 ± 1.40** 30.29 43.96 37.31
3d 0.621 ± 1.60* 0.860 ± 1.72* 0.948 ± 1.88* 1.039 ± 1.67* 29.70 43.62 37.61
3e 0.578 ± 1.58* 0.847 ± 1.28* 0.976 ± 1.18* 1.048 ± 1.21* 20.88 31.37 29.50
3f 0.620 ± 1.62* 0.879 ± 1.25* 1.010 ± 1.30* 1.080 ± 1.42* 23.82 32.75 31.34
3g 0.638 ± 1.35* 0.913 ± 1.27* 1.043 ± 1.38* 1.118 ± 1.46 19.11 30.17 28.35
3h 0.650 ± 1.60** 0.930 ± 1.65** 1.060 ± 1.67** 1.145 ± 1.39** 17.64 29.31 26.11
3i 0.590 ± 1.20* 0.887 ± 1.15* 1.007 ± 1.13* 1.093 ± 1.28* 13.23 28.44 25.22
3j 0.648 ± 1.60** 0.953 ± 1.55** 1.068 ± 1.59** 1.158 ± 1.64** 10.29 27.58 23.88
Data analyzed by one-way ANOVA followed by Dunnett’s test, (n= 6).
Dose levels: Test compounds and diclofenac sodium (25 mg/kg b.w. p.o).
* P< 0.05.
** P< 0.01 signiﬁcant from control.
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treatment. The paw volume of the all groups of rats was mea-
sured using the mercury displacement technique with the help
of digital plethysmometer (UGO BASIL, ITALY) immediately
before and 1, 2 and 3 h after carrageenan injection. The edema
was expressed as a mean reduction in paw volume (ml) after
treatment with tested compounds and anti inﬂammatory activ-
ity % was calculated and summarized in Table 3.
2.4.3. Ulcerogenicity
Ulceration in rats was induced as described by Goyal et al.
(1985). Albino rats of the Wistar strain weighing 150–200 g of
either sex were divided into various groups, each of six animals.
Control group of animals was administered with only 1% car-
boxy methyl cellulose solution in water. One group of animals
was administered with diclofenac sodium and remaining group
was administered with test compounds at a dose of 25 mg/kg
once daily for four days. On the ﬁfth day, pylorus was ligated
as per the method of Shay et al. (1945). Animals were fasted
for 24 h before the pylorus ligation procedure. Four hours after
the ligation, animals were sacriﬁced. The stomach was removed
and opened along with the greater curvature and ulcer index
was determined by the method of Ganguly and Bhatnagar
(1973). The results are summarized in Table 4.
2.4.4. Statistical analysis
Statistical analysis of the biological activity of the synthesized
compounds was evaluated using a one-way analysis of vari-Table 4 Evaluation of ulcer index.
Compound Dose mg/kg/day (p.o.) Time (days) Ulcer index ± SEM
Control CMC 1%w/v 4 –
Standard 25 4 3.10 ± 0.75**
3a 25 4 1.12 ± 0.62**
3c 25 4 0.95 ± 0.45**
3d 25 4 0.90 ± 0.53**
Data analyzed by one-way ANOVA followed by Dunnett’s test,
(n= 6).
** P< 0.01 signiﬁcant from control.ance (ANOVA). In all cases, post hoc comparisons of the
means of individual groups were performed using Dunnett’s
test. A signiﬁcance level of P< 0.05 and P< 0.01 denoted
signiﬁcance in all cases. All values are expressed as mean ± -
SEM. Statistical analysis was carried out using Graph Pad
Prism (Graph Pad Prism 3.0 version).
3. Results and discussion
3.1. Chemistry
Compounds 3a–j were synthesized from reactions of ethyl bism-
ethylthio-2-cyanoacrylate (1) with hydrazides 2 (aromatic hydra-
zides 2a and 2b, aromatic sulfonic acid hydrazides 2c and 2d,
heterocyclic carboxylic acid hydrazides 2e–h, Boc-amino acid
hydrazide 2i and 1-Boc-piperidine-4-carboxylic acid hydrazide
2j) in dimethylformamide in the presence of a catalytic amount
of anhydrous potassium carbonate under reﬂux conditions for
2–3 h. Spectral data (IR, 1H NMR and mass spectra) conﬁrmed
the structures of the synthesized compounds and the purity of
these compounds was ascertained by elemental analyses. The
IR spectra of compounds 3a–j showed the presence of two
absorption bands in the region of 3400–3150 cm1 due to asym-
metric and symmetric stretching of -NH2 groups. The C‚O
stretching of ester groups appeared at 1750–1720 cm1 as a
sharp peak and the C‚O stretching of ketone appeared at
1710–1700 cm1. The S‚O stretching of sulphonyl group ap-
peared as two absorption bands in the range of 1325–1140 cm
1. 1HNMR spectra of compounds 3a–j showed that triplet sig-
nals at d1.23–1.44 due to the CH3 protons of the ethyl group and
quartet signals at d3.85–4.35 due to the CH2 protons of the ethyl
group. They also showed singlet signals within the region of d
2.45–2.57 due to SCH3 protons and broad distinguishable sing-
lets at d 5.45–5.70 corresponding to NH2 protons. The aromatic
protons appeared as multiplets within the region of d 7.05–9.10.
3.2. Analgesic activity
The results of acetic acid induced writhing tests are given in
Table 2. The data showed that all compounds exhibited anal-
264 S.N. Thore et al.gesic activity in the range of 23–57%. It was noticed that com-
pounds 3a, 3c and 3d showed 56.57%, 52.63% and 54.60%
reduction of writhing, respectively, after 1 h of treatment of
tested compounds compared to 63.15% obtained with stan-
dard. The structure and analgesic activity correlation study
showed that compounds with sulfonamidophenyl (3a) and aro-
matic suphonyl group (3c and 3d) are the most active ones.
3.3. Anti-inﬂammatory activity
Anti-inﬂammatory activity was evaluated by carrageenan-in-
duced paw edema test in rats. The activity of the newly synthe-
sized compounds was measured before and at 1, 2 and 3 h after
carrageenan injection. The anti-inﬂammatory activity data (Ta-
ble 3) indicated that all the tested compounds protected rats
from carrageenan-induced inﬂammation reached to peak level
at 2 h then declining in activity was observed at 3 h. All the
tested compounds showed a reasonable inhibition of edema size
ranging from 23.88% to 38.80% compared 40.56% that ob-
tained with diclofenac sodium after 3 h carrageenan injection.
A comparative study of the anti-inﬂammatory activity of
tested compounds relative to the reference drug at different
time intervals indicated the following: After 1 h compound
3a was nearly as effective in inhibiting the paw edema
(32.35%) compared to diclofenac sodium (36.47%). Taking
the anti-inﬂammatory activity after 2 h time interval as a crite-
rion for comparison, it was observed that compounds 3a, 3c
and 3d showed potent anti-inﬂammatory activity 44.48%,
43.96% and 43.62% respectively comparable with diclofenac
sodium (46.20%). Compounds 3b, 3e–g displayed a good
anti-inﬂammatory activity (30–33%).
Compounds 3a, 3c and 3d having sulfonyl group exhibited
good anti-inﬂammatory activity. On the other hand, com-
pounds 3i and 3j showed the least activity.
3.4. Ulcer index
The compounds which showed signiﬁcant anti-inﬂammatory
and analgesic activities have been selected for acute ulceroge-
nicity studies. Ulcerogenic effects of 3a, 3c and 3d were evalu-
ated in rat stress model at acute dose of 25 mg/kg/day for
4 days (Table 4). When compared to the reference standards
diclofenac sodium (ulcer index 3.10 ± 0.75), the tested com-
pounds exhibited 29–35% of the ulcer index of the reference
standards. The compounds 3c and 3d exhibited the lowest ul-
cer index of 0.95 and 0.90 respectively.
4. Conclusion
A series of novel 1H-pyrazole-4-carboxylates were synthesized
and screened for analgesic and anti-inﬂammatory activities.
Most compounds showed moderate to good analgesic and
anti-inﬂammatory activities. Compounds 3a, 3c and 3d exhib-
ited signiﬁcant analgesic and anti-inﬂammatory activities.
Interestingly these compounds showed one-third of the ulcer
index of the reference i.e. diclofenac sodium. Structure and
biological activity relationship of the title compounds showed
that the presence of sulfonamidophenyl and phenylsulphonyl
groups at the N-1 position of pyrazole might be responsible
for analgesic and anti-inﬂammatory activities.Acknowledgments
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